Informations générales (source: ClinicalTrials.gov)
Analysis of Effectiveness and Safety of Teclistamab in Relapsed and Refractory Multiple Myeloma Patients: a Collaborative Janssen - IFM Study IFM 2023-01: TEC-CARE (TEC-CARE)
Observational
Intergroupe Francophone du Myelome (Voir sur ClinicalTrials)
septembre 2023
septembre 2026
29 juin 2024
200 adult patients with multiple myeloma receiving teclistamb will be included.
Effectiveness, safety, and condition of use of teclistamab in early access program
(post-MA) will be assessed. Primary objective is the evaluation of overall response rate
(ORR) of teclistamab according to IMWG criteria.
This is a multicenter, prospective, observational study.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| HOPITAL NOVO | BENRAMDANE | 04/07/2024 11:05:06 | Contacter | ||
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| AP-HP - Hôpital Necker-Enfants Malades | FRENZEL Laurent, MD | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| CH Bretagne Atlantique - Vannes - France | Brieuc CHEREL, MD | Contact (sur clinicalTrials) | |||
| CH d'ANNECY - Annecy - France | Frederique ORSINI-PIOCELLE | Contact (sur clinicalTrials) | |||
| CH de METZ - Metz - France | Véronique Dorvaux, MD | Contact (sur clinicalTrials) | |||
| CH Dunkerque - Dunkerque - France | Helene DEMARQUETTE, MD | Contact (sur clinicalTrials) | |||
| CH Perpignan - Perpignan - France | Virginie ROLLAND, MD | Contact (sur clinicalTrials) | |||
| CHU Bordeaux - 31400 - Bordeaux - France | Cyrille HULIN, MD | Contact (sur clinicalTrials) | |||
| CHU CAEN - Caen - France | Margaret MACRO, MD | Contact (sur clinicalTrials) | |||
| CHU de Lille - Lille - France | Salomon MANIER, MD, PHD | Contact (sur clinicalTrials) | |||
| CHU de Lyon - Lyon - France | Lionel KARLIN, MD | Contact (sur clinicalTrials) | |||
| Chu de Nantes - Nantes - France | Cyrille TOUZEAU, MD, PHD | Contact (sur clinicalTrials) | |||
| CHU de Nice - Nice - France | Valentine RICHEZ-OLIVIER, MD | Contact (sur clinicalTrials) | |||
| Chu de Rennes - Rennes - France | Olivier DECAUX, MD. PHD | Contact (sur clinicalTrials) | |||
| CHU de Tours - Tours - France | Thomas CHALOPIN, MD | Contact (sur clinicalTrials) | |||
| Chu Dijon - Dijon - France | Andréa PIERAGOSTINI | Contact (sur clinicalTrials) | |||
| CHU Toulouse - Toulouse - France | Aurore PERROT, MD; PHD | Contact (sur clinicalTrials) | |||
| Hopital de la cote Basque - Bayonne - France | Julie GAY, MD | Contact (sur clinicalTrials) | |||
| Hopital saint louis - Paris - France | Bertrand ARNULF, MD | Contact (sur clinicalTrials) | |||
| Institut Paoli Calmette - Marseille - France | Jean-Marc SCHIANO DE COLELLA, MD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Adult patient (≥18 years) with multiple myeloma who will receive at least one dose
of teclistamab (first dose of the step-up dose)
- Adult patient (≥18 years) with multiple myeloma who will receive at least one dose
of teclistamab (first dose of the step-up dose)
- Patients alive at the start of the study who did not receive study information or
who objected to the collection of data
- Patients who received teclistamab as part of an interventional clinical trial
- Patients who are initiating teclistamab as part of a current interventional clinical
trial